Acute haemodynamic responses to inhaled nitric oxide and intravenous sildenafil in distal chronic thromboembolic pulmonary hypertension (CTEPH)

被引:28
作者
Suntharalingam, J. [1 ]
Hughes, R. J. [1 ]
Goldsmith, K. [1 ]
Doughty, N. [1 ]
George, P. [1 ]
Toshner, M. [1 ]
Sheares, K. K. [1 ]
Pepke-Zaba, J. [1 ]
机构
[1] Papworth Hosp NHS TRust, Pulm Vasc Dis Unit, Papworth Everard CB3 8RE, Cambs, England
基金
英国医学研究理事会;
关键词
thromboembolic; pulmonary hypertension; vasoreactivity; sildenafil; nitric oxide;
D O I
10.1016/j.vph.2007.01.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Introduction: Although surgery is the treatment of choice for CTEPH, it is not appropriate for patients with surgically inaccessible distal disease. These patients are traditionally managed supportively, but may benefit from newer, more specific vasoactive therapies. This study examines the acute haemodynamic responses to inhaled nitric oxide (iNO) and intravenous sildenafil in this patient population. Methods: Nine patients with de novo distal CTEPH and nine with persistent pulmonary hypertension post-pulmonary endarterectomy (PEA) were enrolled. At right heart catheterisation, following baseline haemodynamic measurements, iNO was administered at 20 ppm for 10 min. Following repeat measurements, iNO was discontinued with a subsequent washout period of 10 min. Sildenafil was then administered intravenously at two doses, to achieve plasma levels equivalent to 25 mg and 50 mg orally, with further measurements obtained at the end of each infusion. Results: Significant reductions in mean pulmonary artery pressure (mPAP) and pulmonary vascular resistance (PVR) were demonstrated following both iNO (-4.3 mm Hg or -10.3% p=0.001 and -101 dyn/s/cm(5) or - 15.6% p < 0.001) and sildenafil (-7.4 mm Hg or -16.9% p < 0.001 and -188.8 dyn/s/cm(5) or -25.1% p < 0.001). Individual mPAP and cardiac output (CO) responses to iNO and sildenafil correlated well, but haemodynamic changes following sildenafil were consistently more marked. There was, however, no difference in effect between the two doses of sildenafil. Although sildenafil caused significant reductions in systemic vascular resistance, the net haemodynamic effect of sildenafil remained pulmonary selective. Subgroup analysis suggested that post-PEA patients were more responsive to both iNO and sildenafil than de novo patients. Discussion: Although all but one patient failed to fulfil the formal haemodynamic response criteria typically used in idiopathic pulmonary arterial hypertension (IPAH), subjects displayed significant acute responses to both iNO and sildenafil suggesting that increased vascular tone forrns an important component of distal CTEPH. It is possible that these acute haemodynamic responses may translate to improved clinical outcomes, and thus further long term trials of sildenafil in distal CTEPH are warranted. (c) 2007 Published by Elsevier Inc.
引用
收藏
页码:449 / 455
页数:7
相关论文
共 32 条
[1]   Medical therapy for pulmonary arterial hypertension - ACCP evidence-based clinical practice guidelines [J].
Badesch, DB ;
Abman, SH ;
Ahearn, GS ;
Barst, RJ ;
McCrory, DC ;
Simonneau, G ;
McLaughlin, VV .
CHEST, 2004, 126 (01) :35S-62S
[2]   Continuous intravenous epoprostenol for chronic thromboembolic pulmonary hypertension [J].
Bresser, P ;
Fedullo, PF ;
Auger, WR ;
Channick, RN ;
Robbins, IM ;
Kerr, KM ;
Jamieson, SW ;
Rubin, LJ .
EUROPEAN RESPIRATORY JOURNAL, 2004, 23 (04) :595-600
[3]  
Bresser Paul, 2006, Proc Am Thorac Soc, V3, P594, DOI 10.1513/pats.200605-115LR
[4]   Cyclic GMP phosphodiesterase-5: Target of sildenafil [J].
Corbin, JD ;
Francis, SH .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1999, 274 (20) :13729-13732
[5]   Sildenafil citrate therapy for pulmonary arterial hypertension [J].
Galiè, N ;
Ghofrani, HA ;
Torbicki, A ;
Barst, RJ ;
Rubin, LJ ;
Badesch, D ;
Fleming, T ;
Parpia, T ;
Burgess, G ;
Branzi, A ;
Grimminger, F ;
Kurzyna, M ;
Simonneau, G .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (20) :2148-2157
[6]   Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension - A randomized prospective study [J].
Ghofrani, HA ;
Voswinckel, R ;
Reichenberger, F ;
Olschewski, H ;
Haredza, P ;
Karadas, B ;
Schermuly, RT ;
Weissmann, N ;
Seeger, W ;
Grimminger, F .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 44 (07) :1488-1496
[7]   Sildenafil for long-term treatment of nonoperable chronic thromboembolic pulmonary hypertension [J].
Ghofrani, HA ;
Schermuly, RT ;
Rose, F ;
Wiedemann, R ;
Kohstall, MG ;
Kreckel, A ;
Olschewski, H ;
Weissmann, N ;
Enke, B ;
Ghofrani, S ;
Seeger, W ;
Grimminger, F .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 167 (08) :1139-1141
[8]   Dose response of intravenous sildenafil on systemic and regional hemodynamics in hypoxic neonatal piglets [J].
Haase, Erika ;
Bigam, David L. ;
Cravetchi, Olga ;
Cheung, Po-Yin .
SHOCK, 2006, 26 (01) :99-106
[9]   Goal-oriented treatment and combination therapy for pulmonary arterial hypertension [J].
Hoeper, MM ;
Markevych, I ;
Spiekerkoetter, E ;
Welte, T ;
Niedermeyer, J .
EUROPEAN RESPIRATORY JOURNAL, 2005, 26 (05) :858-863
[10]   The efficacy of bosentan in inoperable chronic thromboembolic pulmonary hypertension: a 1-year follow-up study [J].
Hughes, R. J. ;
Jais, X. ;
Bonderman, D. ;
Suntharalingam, J. ;
Humbert, M. ;
Lang, I. ;
Simonneau, G. ;
Pepke-Zaba, J. .
EUROPEAN RESPIRATORY JOURNAL, 2006, 28 (01) :138-143